UCB In-licenses Parkinson's Drug - Analyst Blog


UCB ( UCBJF ) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson's disease from Biotie Therapies.

The Candidate

Tozadenant is an orally administered, selective inhibitor of the adenosine 2a receptor, which is being developed for the treatment of Parkinson's disease.

UCB's decision to in-license the candidate was based on encouraging results from a double-blind, randomized, placebo-controlled phase IIb study that evaluated tozadenant as an adjunctive therapy in levodopa-treated Parkinson's disease patients. Phase III program will be conducted by Biotie for which patient enrolment will start by the first half of 2015.

Terms of the Deal

UCB and Biotie had initially announced their collaboration in 2010. However, with the in-licensing of tozadenant, the original agreement has been modified. Biotie will now receive an upfront payment of $20 million from UCB. Under the original agreement, Biotie was supposed to receive an additional $340 million on the achievement of future milestones. Under the revised deal, Biotie will receive additional amounts in the low triple-digit millions in total, over the next six years, on the achievement of defined development, regulatory and commercialization milestones. Both UCB and Biotie will work on the ongoing clinical development of this candidate. Manufacturing and commercialization of tozadenant will be handled by UCB.

Our Take

This licensing deal represents UCB's efforts to strengthen its Parkinson's disease portfolio. The company currently has Neupro in its portfolio for the symptomatic treatment of all stages of idiopathic Parkinson's disease.

UCB carries a Zacks Rank #3 (Hold). Currently, companies like Lannett Company, Inc. ( LCI ), SIGA Technologies, Inc. ( SIGA ) and QLT Inc. ( QLTI ) look more attractive with a Zacks Rank #1 (Strong Buy).

LANNETT INC (LCI): Free Stock Analysis Report

QLT INC (QLTI): Free Stock Analysis Report

SIGA TECH INC (SIGA): Free Stock Analysis Report

UCB SA (UCBJF): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: LCI , QLTI , SIGA , UCBJF



More from Zacks.com:

Related Videos



Most Active by Volume

  • $38.53 ▼ 5.86%
  • $17.05 ▲ 0.59%
  • $89.83 ▼ 4.32%
  • $101.075 ▲ 0.11%
  • $5.2329 ▼ 2.19%
  • $98.785 ▼ 1.20%
  • $11.39 ▼ 5.08%
  • $3.5441 ▼ 0.73%
As of 9/22/2014, 12:22 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com